Preoperative  inhibition in patients with irresectable locally advanced stage III melanoma

Marloes Faut; Mathilde Jalving; Gilles F Diercks; Geke A Hospers; Barbara L van Leeuwen; Lukas B Been

doi:10.2217/mmt-2018-0002

Preoperative inhibition in patients with irresectable locally advanced stage III melanoma

Marloes Faut, Mathilde Jalving, Gilles F Diercks, Geke A Hospers, Barbara L van Leeuwen, Lukas B Been

Onderzoeksoutput › Academic › peer review

165 Downloads (Pure)

Samenvatting

Aim: Neoadjuvant treatment of locally advanced disease with BRAF inhibitors is expected to increase the likelihood of a R0 resection. We present six patients with stage III unresectable melanoma, neoadjuvantly treated with BRAF inhibitors.

Methods: Patients with unresectable, BRAF-mutated, stage III melanoma, were treated with BRAF inhibitors between 2012 and 2015. Unresectability was determined based on clinical and/or radiological findings. At maximal response, resection was performed. The specimen was reviewed to determine the degree of response.

Results: In five of six patients a radical resection was achieved. Postoperative complications were unremarkable. In five of six resected specimens, vital tumor tissue was found.

Conclusion: Neoadjuvant BRAF inhibitor treatment of locally advanced melanoma is feasible and has the potential to facilitate an R0 resection.

Originele taal-2	English
Artikelnummer	MMT08
Aantal pagina's	10
Tijdschrift	Melanoma management
Volume	5
Nummer van het tijdschrift	2
DOI's	https://doi.org/10.2217/mmt-2018-0002
Status	Published - jun.-2018

Toegang tot document

10.2217/mmt-2018-0002Licentie: CC BY-NC-ND

Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanomaFinal publisher's version, 5,8 MBLicentie: CC BY-NC-ND

Handle.net

Permanente koppeling

Citeer dit

@article{8be1aa7ee21640b5ae25e3ec2ea1ce5d,

title = "Preoperative inhibition in patients with irresectable locally advanced stage III melanoma",

abstract = "Aim: Neoadjuvant treatment of locally advanced disease with BRAF inhibitors is expected to increase the likelihood of a R0 resection. We present six patients with stage III unresectable melanoma, neoadjuvantly treated with BRAF inhibitors.Methods: Patients with unresectable, BRAF-mutated, stage III melanoma, were treated with BRAF inhibitors between 2012 and 2015. Unresectability was determined based on clinical and/or radiological findings. At maximal response, resection was performed. The specimen was reviewed to determine the degree of response.Results: In five of six patients a radical resection was achieved. Postoperative complications were unremarkable. In five of six resected specimens, vital tumor tissue was found.Conclusion: Neoadjuvant BRAF inhibitor treatment of locally advanced melanoma is feasible and has the potential to facilitate an R0 resection.",

keywords = "PHASE-3, CANCER, RANDOMIZED CONTROLLED-TRIAL, NEOADJUVANT TREATMENT, METASTATIC MELANOMA, HIGH-RISK, SURVIVAL, VEMURAFENIB, DABRAFENIB, IPILIMUMAB",

author = "Marloes Faut and Mathilde Jalving and Diercks, {Gilles F} and Hospers, {Geke A} and {van Leeuwen}, {Barbara L} and Been, {Lukas B}",

year = "2018",

month = jun,

doi = "10.2217/mmt-2018-0002",

language = "English",

volume = "5",

journal = "Melanoma management",

issn = "2045-0885",

publisher = "FUTURE MEDICINE LTD",

number = "2",

}

TY - JOUR

T1 - Preoperative inhibition in patients with irresectable locally advanced stage III melanoma

AU - Faut, Marloes

AU - Jalving, Mathilde

AU - Diercks, Gilles F

AU - Hospers, Geke A

AU - van Leeuwen, Barbara L

AU - Been, Lukas B

PY - 2018/6

Y1 - 2018/6

N2 - Aim: Neoadjuvant treatment of locally advanced disease with BRAF inhibitors is expected to increase the likelihood of a R0 resection. We present six patients with stage III unresectable melanoma, neoadjuvantly treated with BRAF inhibitors.Methods: Patients with unresectable, BRAF-mutated, stage III melanoma, were treated with BRAF inhibitors between 2012 and 2015. Unresectability was determined based on clinical and/or radiological findings. At maximal response, resection was performed. The specimen was reviewed to determine the degree of response.Results: In five of six patients a radical resection was achieved. Postoperative complications were unremarkable. In five of six resected specimens, vital tumor tissue was found.Conclusion: Neoadjuvant BRAF inhibitor treatment of locally advanced melanoma is feasible and has the potential to facilitate an R0 resection.

AB - Aim: Neoadjuvant treatment of locally advanced disease with BRAF inhibitors is expected to increase the likelihood of a R0 resection. We present six patients with stage III unresectable melanoma, neoadjuvantly treated with BRAF inhibitors.Methods: Patients with unresectable, BRAF-mutated, stage III melanoma, were treated with BRAF inhibitors between 2012 and 2015. Unresectability was determined based on clinical and/or radiological findings. At maximal response, resection was performed. The specimen was reviewed to determine the degree of response.Results: In five of six patients a radical resection was achieved. Postoperative complications were unremarkable. In five of six resected specimens, vital tumor tissue was found.Conclusion: Neoadjuvant BRAF inhibitor treatment of locally advanced melanoma is feasible and has the potential to facilitate an R0 resection.

KW - PHASE-3

KW - CANCER

KW - RANDOMIZED CONTROLLED-TRIAL

KW - NEOADJUVANT TREATMENT

KW - METASTATIC MELANOMA

KW - HIGH-RISK

KW - SURVIVAL

KW - VEMURAFENIB

KW - DABRAFENIB

KW - IPILIMUMAB

U2 - 10.2217/mmt-2018-0002

DO - 10.2217/mmt-2018-0002

M3 - Article

C2 - 30459939

VL - 5

JO - Melanoma management

JF - Melanoma management

SN - 2045-0885

IS - 2

M1 - MMT08

ER -